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CASE REPORT
Abstract: This report is the first to describe the use of milnacipran and olanzapine in
combination in the treatment of delusional depression. The patient was a 55-year-old woman,
and the combination treatment brought her marked amelioration of delusional depression
without significant side effects. This suggests that the combination therapy of milnacipran
and olanzapine is efficacious and safe in the treatment of delusional depression.
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Introduction
Depression with psychotic features responds poorly to treatment with a tricyclic
antidepressant or a conventional antipsychotic alone, but their combination shows a
clearly preferable therapeutic effect (Spiker et al 1985). Recently, Rothschild et al
(2004) reported that the combination therapy of a selective serotonin reuptake inhibitor
(SSRI) (fluoxetine) and an atypical antipsychotic (olanzapine) showed a significantly
higher response rate than placebo or olanzapine monotherapy and exhibited
extrapyramidal symptoms comparable with placebo. The combination therapy of
newer drugs is preferable from the point of view of side effects.
Milnacipran is a novel antidepressant that selectively inhibits the reuptake of
serotonin and noradrenaline without directly affecting the postsynaptic receptor sites,
and its response and remission rate has been reported to be higher than SSRIs
(Montgomery et al 1996). The combination therapy of milnacipran and a newer
antipsychotic drug may therefore exhibit better therapeutic effects on depression
with psychotic features than that of an SSRI and a newer antipsychotic drug. To our
knowledge, this is the first report on the marked effect of milnacipran combined with
olanzapine for treating a delusional depressive patient.
Case report
The patient was a 55-year-old homemaker who had no past history of psychiatric
disorders. She worked hard looking after her bedridden mother-in-law. In 1998, she
suffered from depression accompanied by a delusion of poverty. She was treated
with 5 mg/d of haloperidol and 150 mg/d of trazodone. Almost one month after the
therapy was started, her symptoms of depression with delusion remitted. Although
she was informed about the disadvantage of long-term treatment with a conventional
antipsychotic drug, she wished to continue this medication because of fear of relapse.
Her medication regime continued unchanged for 3 years.
In April 2001, she was diagnosed with drug-induced parkinsonism and her
haloperidol was stopped. Two months later, she again suffered from depression
accompanied by irritation and loss of appetite and activity. She also suffered from
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persecutory delusion. The patient was diagnosed with major
depression with psychotic features (DSM-IV). On July 3rd,
2001, she was hospitalized and started on 2 mg/d of
risperidone in addition to 100 mg/d of trazodone. She
developed severe akathisia, so administration of risperidone
was stopped and treatment with 10 mg/d of olanzapine was
started on July 6th, 2001. Her akathisia did not reappear
and her anxiety gradually decreased. Five days later,
trazodone was stopped and milnacipran 50 mg/day was
started because her anorexia and hypobulia still persisted.
Later that month, her facial expression was not depressive
and her anorexia had remitted; however, the delusions that
caused her to refer to herself as a “pig” and a “fool” still
remained. On August 8th, 2001, the tendency to make
delusional remarks disappeared and her loss of both volition
and activity remitted. The dosage of milnacipran was
increased to 100 mg/d because this dosage was reported to
be effective in the reduction of recurrences (Rouillon et al
2000). The combination therapy of both olanzapine and
milnacipran caused no adverse events.
The patient was discharged a month later and her
medication was continued without change. In February
2002, her appetite increased and the olanzapine was reduced
to 5 mg/d. In March 2002, the milnacipran was reduced to
50 mg/d because her increased appetite persisted. She
stopped visiting our hospital by her own decision in February
2003. In October 2003, she again suffered from depression,
persecutory delusion, and anorexia and revisited our
hospital. She was started on 100 mg/d of milnacipran and
5 mg/d of olanzapine. Milnacipran 100 mg/d was prescribed
because this dosage was reported to be optimal
(Montgomery et al 1996). Four weeks after the therapy was
started, the patient’s depressive mood and delusions
disappeared completely. About two years have passed since
the last episode remitted. Her medication has continued
unchanged and her depressive symptoms have not returned.
Discussion
In this case, risperidone induced severe akathisia and
replacing it with olanzapine produced good results. Both
SSRIs and serotonin-noradrenaline reuptake inhibitors
(SNRIs) would be candidates for combination with
olanzapine in the treatment of depression with psychotic
features as they have fewer side effects. Milnacipran has
much lower interindividual variation in plasma levels than
SSRIs: it does not induce/inhibit hepatic P450 enzymes and
therefore has a very low potential for drug–drug interactions
(Puozzo et al 2002). These characteristics of milnacipran
make it preferable for use in the drug combination therapy
of depression with psychotic features.
This case suggests that the combination therapy of
milnacipran and olanzapine is effective and safe compared
with the traditional combination therapy of tricyclic
antidepressants and typical antipsychotics for the treatment
of delusional depression.
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